Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$216.03 USD

216.03
2,374,438

+14.07 (6.97%)

Updated Jun 26, 2026 04:00 PM ET

After-Market: $215.70 -0.33 (-0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.94%
2Buy18.19%
3Hold10.25%
4Sell5.78%
5Strong Sell3.18%
S&P50011.60%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (154 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up

by Zacks Equity Research

DNLI maps 2026 goals as it awaits FDA action on tividenofusp alfa, targeting first commercial validation amid multiple late-stage readouts.

Sundeep Ganoria headshot

Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth

by Sundeep Ganoria

ABBV's neuroscience franchise now drives more than 17% of revenues, with strong Botox, Vraylar and migraine drug sales fueling double-digit growth.

Ekta Bagri headshot

Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?

by Ekta Bagri

Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.

Zacks Equity Research

Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ekta Bagri headshot

Denali Enters Into a $275M Funding Deal With Royalty Pharma

by Ekta Bagri

DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.

Zacks Equity Research

Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report?

by Zacks Equity Research

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline

by Zacks Equity Research

BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.

Sundeep Ganoria headshot

Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3

by Sundeep Ganoria

ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.

Aparajita Dutta headshot

Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month

by Aparajita Dutta

As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.

Zacks Equity Research

DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug

by Zacks Equity Research

Denali's Q3 loss widens year over year as expenses rise, while the FDA delays its review of the firm???s key Hunter syndrome therapy to 2026.